CN112843014A - 骨化二醇软胶囊 - Google Patents

骨化二醇软胶囊 Download PDF

Info

Publication number
CN112843014A
CN112843014A CN202110038958.XA CN202110038958A CN112843014A CN 112843014 A CN112843014 A CN 112843014A CN 202110038958 A CN202110038958 A CN 202110038958A CN 112843014 A CN112843014 A CN 112843014A
Authority
CN
China
Prior art keywords
soft capsule
pharmaceutically acceptable
calcifediol
acid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110038958.XA
Other languages
English (en)
Chinese (zh)
Inventor
约瑟普·马里亚·苏涅·内格雷
伊格纳西奥·奥尔特加·阿斯皮塔特
佩帕·德尔阿雷纳尔·巴里奥斯
贡萨洛·埃尔南德斯·埃雷罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Faes Farma SA
Original Assignee
Faes Farma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52462260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN112843014(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Faes Farma SA filed Critical Faes Farma SA
Publication of CN112843014A publication Critical patent/CN112843014A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Paints Or Removers (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Lubricants (AREA)
  • Carbon And Carbon Compounds (AREA)
CN202110038958.XA 2015-02-06 2016-02-05 骨化二醇软胶囊 Pending CN112843014A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15382042.8 2015-02-06
EP15382042.8A EP3053598A1 (en) 2015-02-06 2015-02-06 Calcifediol soft capsules
CN201680004162.XA CN106999441B (zh) 2015-02-06 2016-02-05 骨化二醇软胶囊

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680004162.XA Division CN106999441B (zh) 2015-02-06 2016-02-05 骨化二醇软胶囊

Publications (1)

Publication Number Publication Date
CN112843014A true CN112843014A (zh) 2021-05-28

Family

ID=52462260

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110038958.XA Pending CN112843014A (zh) 2015-02-06 2016-02-05 骨化二醇软胶囊
CN201680004162.XA Active CN106999441B (zh) 2015-02-06 2016-02-05 骨化二醇软胶囊

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680004162.XA Active CN106999441B (zh) 2015-02-06 2016-02-05 骨化二醇软胶囊

Country Status (31)

Country Link
US (1) US10525018B2 (enExample)
EP (3) EP3053598A1 (enExample)
JP (2) JP6427270B2 (enExample)
KR (1) KR101971384B1 (enExample)
CN (2) CN112843014A (enExample)
AU (1) AU2016214336B2 (enExample)
BR (1) BR112017010657B1 (enExample)
CA (1) CA2967170C (enExample)
CL (1) CL2017001335A1 (enExample)
CO (1) CO2017004545A2 (enExample)
CY (1) CY1122976T1 (enExample)
DK (2) DK3204047T3 (enExample)
EA (1) EA034821B1 (enExample)
ES (2) ES2738642T3 (enExample)
HR (1) HRP20200859T1 (enExample)
HU (1) HUE050133T2 (enExample)
LT (1) LT3204047T (enExample)
MA (2) MA52507A (enExample)
MD (1) MD3204047T2 (enExample)
ME (1) ME03739B (enExample)
MX (1) MX367999B (enExample)
MY (2) MY199862A (enExample)
PE (1) PE20170911A1 (enExample)
PH (1) PH12017501350A1 (enExample)
PL (1) PL3204047T3 (enExample)
PT (1) PT3204047T (enExample)
RS (2) RS64166B1 (enExample)
SI (1) SI3204047T1 (enExample)
SM (1) SMT202000278T1 (enExample)
WO (1) WO2016124724A1 (enExample)
ZA (1) ZA201703444B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3053598A1 (en) 2015-02-06 2016-08-10 Faes Farma, S.A. Calcifediol soft capsules
CN108542908A (zh) * 2018-06-08 2018-09-18 唐飞 25-羟基维生素d3在制备治疗或预防肝性骨病药物中的应用
CN120154576A (zh) 2018-08-31 2025-06-17 欧普科爱尔兰环球控股有限公司 儿童剂型、制造和使用方法
CN109662953B (zh) * 2019-02-18 2022-05-10 威海金思力生物科技股份有限公司 一种维生素d软胶囊及其制作方法
WO2021011538A1 (en) * 2019-07-15 2021-01-21 R.P. Scherer Technologies, Llc Capsule dosage forms, methods of preparation and methods of use thereof
WO2021033003A1 (en) * 2019-08-22 2021-02-25 Industrial Technologies & Biotechnologies Hormone d (vitamin d) and its derivatives for the treatment and prevention of cancer
CN113559079B (zh) * 2020-04-28 2023-10-20 江苏恒瑞医药股份有限公司 一种软胶囊及其制备方法和用途
WO2022103636A1 (en) * 2020-11-16 2022-05-19 Orcosa Inc. Improved use of cannabinoids in the treatment of alzheimer's disease
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022224001A1 (en) 2021-04-22 2022-10-27 Faes Farma, S.A. Universal dosage regime of 25-hydroxy vitamin d3
CN114159402A (zh) * 2021-12-21 2022-03-11 湖州展望天明药业有限公司 一种不透明植物胶囊及其制备方法
CN116350598A (zh) * 2021-12-28 2023-06-30 人福普克药业（武汉）有限公司 一种用于维生素d类药物的成膜组合物及其药物制剂和制备方法
CN114712505B (zh) * 2022-03-10 2023-09-05 南方医科大学南方医院 维生素d受体激动剂在制备预防和/或治疗炎症性骨丢失的药物中的应用
CN120282775A (zh) * 2022-12-14 2025-07-08 R·P·谢勒技术有限公司 软凝胶胶囊和制备软凝胶胶囊的方法
CN116270520A (zh) * 2023-03-03 2023-06-23 正大制药（青岛）有限公司 一种维生素d胶囊型滴剂及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4532126A (en) 1982-05-07 1985-07-30 R. P. Scherer Corporation Masticatory soft elastic gelatin capsules and method for the manufacture thereof
GB8305693D0 (en) 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
JPS6335411A (ja) 1986-07-29 1988-02-16 Tonen Sekiyukagaku Kk 高純度合成石英の製造方法
US4997824A (en) 1987-07-22 1991-03-05 Teva Pharmaceutical Industries Ltd. Combination of cholecalciferol derivatives for the treatment of renal bone disease
JPH04288016A (ja) 1991-03-14 1992-10-13 Tokai Capsule Kk 活性型ビタミンｄ３類軟カプセル剤の製造方法
JPH054925A (ja) 1991-06-27 1993-01-14 Teikoku Chem Ind Corp Ltd アルフアカルシドール軟カプセル製剤
JP2684587B2 (ja) 1993-06-21 1997-12-03 呉羽化学工業株式会社 腎性骨異栄養症における骨量減少抑制剤
US6340473B1 (en) 1999-07-07 2002-01-22 R.P. Scherer Technologies, Inc. Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
US6893658B1 (en) * 1999-08-31 2005-05-17 Chugai Seiyaku Kabushiki Kaisha Soft capsules
US6251426B1 (en) 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
JP2005515996A (ja) 2001-12-03 2005-06-02 ノバセア インコーポレイティッド 活性型ビタミンｄ化合物を含む薬学的組成物
US7632518B2 (en) * 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
US20030158264A1 (en) * 2002-02-20 2003-08-21 Ramachandran Radhakrishnan Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same
WO2003070156A2 (en) 2002-02-20 2003-08-28 Strides Arcolab Limited Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same
JP2005531532A (ja) 2002-04-05 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド アレンドロナートおよびビタミンｄ製剤を用いる骨吸収阻害法
US7438903B2 (en) 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
US7332482B2 (en) 2003-09-24 2008-02-19 Bioxell S.P.A. Method for treating benign prostatic hyperplasia
US20050142185A1 (en) 2003-12-29 2005-06-30 Beleno Alfredo B. Softgel formulations of bisphosphonates bone resorption inhibitors
US20050152969A1 (en) 2004-01-08 2005-07-14 Chiprich Timothy B. Colored liquid-filled soft capsules and method of manufacture thereof
US20050175686A1 (en) 2004-02-11 2005-08-11 Ramachandran Radhakrishnan Drug delivery system using a solubilized gelatin shell composition and unit dose drug delivery using a special shape soft gelatin capsule
US20060009425A1 (en) 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
CA2570649A1 (en) 2004-06-07 2005-12-22 Strides Arcolab Limited Pharmaceutical composition containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same
AU2006294819A1 (en) 2005-09-26 2007-04-05 Novacea, Inc. Prevention and treatment of gastrointestinal and bladder disorders using active vitamin D compounds
US20070098819A1 (en) * 2005-11-02 2007-05-03 Susan Thys-Jacobs Micronutrient supplement with calcium, vitamin D or calcium & vitamin D combination for premenstrual syndrome, postpartum depression, depression and panic attacks
EP1993559B1 (en) 2006-02-03 2016-06-22 OPKO Renal, LLC Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
US8501717B2 (en) * 2007-02-09 2013-08-06 Merck, Sharp & Dohme Corp. Methods to treat and/or prevent mucositis
HRP20231142T3 (hr) * 2007-04-25 2024-01-05 Eirgen Pharma Ltd. Kontrolirano oslobađanje 25-hidroksivitamina d
CA2683628C (en) 2007-04-25 2018-03-06 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
US8759328B2 (en) 2008-07-24 2014-06-24 Wisconsin Alumni Research Foundation Once-a-week administration of 25-hydroxy vitamin D3 to sustain elevated steady-state pharmacokinetic blood concentration
CN102307576A (zh) 2008-12-15 2012-01-04 班纳制药公司 用于增强水不溶性活性剂的释放和吸收的方法
US9011908B2 (en) 2009-04-06 2015-04-21 Banner Life Sciences Llc Progesterone solutions for increased bioavailability
WO2012047098A1 (en) 2010-10-04 2012-04-12 Dishman Pharmaceuticals And Chemicals Ltd. Encapsulated fat-soluble vitamin
GB201216385D0 (en) 2012-09-13 2012-10-31 Chrysalis Pharma Ag A pharmaceutical composition
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
EP3053598A1 (en) 2015-02-06 2016-08-10 Faes Farma, S.A. Calcifediol soft capsules

Also Published As

Publication number Publication date
JP2018184458A (ja) 2018-11-22
MA52507A (fr) 2021-03-10
MX367999B (es) 2019-09-12
ES2738642T3 (es) 2020-11-06
CN106999441B (zh) 2020-11-24
RS60467B1 (sr) 2020-07-31
ME03739B (me) 2021-01-20
EP3053598A1 (en) 2016-08-10
CL2017001335A1 (es) 2018-01-19
JP6697779B2 (ja) 2020-05-27
PE20170911A1 (es) 2017-07-12
KR20170093123A (ko) 2017-08-14
EA034821B1 (ru) 2020-03-25
CO2017004545A2 (es) 2017-08-31
RS64166B1 (sr) 2023-05-31
MX2017006272A (es) 2017-08-14
SI3204047T1 (sl) 2020-07-31
EA201791097A1 (ru) 2017-08-31
US10525018B2 (en) 2020-01-07
LT3204047T (lt) 2020-07-10
BR112017010657B1 (pt) 2022-10-11
WO2016124724A1 (en) 2016-08-11
SMT202000278T1 (it) 2020-07-08
US20170348249A1 (en) 2017-12-07
MD3204047T2 (ro) 2020-06-30
CA2967170A1 (en) 2016-08-11
JP6427270B2 (ja) 2018-11-21
AU2016214336B2 (en) 2017-10-19
CA2967170C (en) 2018-06-05
AU2016214336A1 (en) 2017-05-25
ES2738642T1 (es) 2020-01-24
ZA201703444B (en) 2019-09-25
MA41058B1 (fr) 2020-05-29
KR101971384B1 (ko) 2019-04-22
KR101971384B9 (ko) 2022-07-25
PL3204047T3 (pl) 2020-08-24
EP3204047B1 (en) 2020-05-27
ES2941385T3 (es) 2023-05-22
HRP20200859T1 (hr) 2020-08-21
PT3204047T (pt) 2020-06-05
HUE050133T2 (hu) 2020-11-30
BR112017010657A2 (pt) 2018-02-14
EP3689380B1 (en) 2023-03-15
CN106999441A (zh) 2017-08-01
DK3689380T3 (da) 2023-05-22
EP3204047A1 (en) 2017-08-16
PH12017501350A1 (en) 2017-12-18
MY199862A (en) 2023-11-25
DK3204047T3 (da) 2020-06-02
EP3689380A1 (en) 2020-08-05
JP2017536358A (ja) 2017-12-07
MY189432A (en) 2022-02-11
CY1122976T1 (el) 2021-10-29

Similar Documents

Publication Publication Date Title
JP6697779B2 (ja) カルシフェジオール軟カプセル剤
JP7071420B2 (ja) 親油性の化合物の固体経口剤形
CN105263462B (zh) 无明胶肠溶软胶囊
EP2062571B1 (en) Self-emulsifying pharmaceutical composition with enhanced bioavailability
TWI694823B (zh) 含有脂質化合物、三酸甘油酯及界面活性劑之組成物與使用該組成物之方法
TW200950799A (en) Compositions of GnRH related compounds and processes of preparation
CN107405326A (zh) ω3脂肪酸的自乳化组合物
WO2012013331A2 (en) Capsules of active pharmaceutical ingredients and polyunsaturated fatty acids for the treatment of prostate diseases
NL2023661B1 (en) Pharmaceutical Eutectic Salt Formulation
CN106256345A (zh) 维生素c传递系统及其脂质体组合物
CN105796530A (zh) 用于降低甲状旁腺水平的方法和组合物
US9585896B2 (en) Compositions comprising omega-3 fatty acids and vitamin D for psoriasis, and methods and uses thereof
JPH0840936A (ja) 経口投与薬物のための製剤
WO2015121378A1 (en) Liquid phospholipid-containing compositions for the preparation of pharmaceuticals
HK40034919A (en) Calcifediol soft capsules
HK40034919B (en) Calcifediol soft capsules
Higashino et al. Control of oral absorption of nutritional supplement using lipid-based formulations (LBFs): Application to the poorly water-soluble ingredient
HK1235289B (en) Calcifediol soft capsules
HK1235289A1 (en) Calcifediol soft capsules

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination